Thomas O. Hecht

Thomas O.
Hecht was the founder of HHC consulting, founded in 2002, and Cell Medica Switzerland AG, founded in 2009, where he served as Executive Chairman from 2014 to 2016.
Current jobs include Chairman-Supervisory Board at Affimed NV since 2007, Chairman-Supervisory Board at Affimed AG since 2005, Chairman at Orion Biotechnology Canada Ltd. since 2019, Chairman-Supervisory Board at Affimed GmbH since 2007, Chairman at Aelix Therapeutics SL since 2017, and President & Director at Haemosan, Inc. Former jobs include Chairman & Chief Executive Officer at Telormedix SA from 2009 to 2011, Executive Chairman at Cytos Biotechnology AG from 2003 to 2012, Chairman at ESBATech, a Novartis Co. GmbH from 2004 to 2009, Chairman at Vaximm AG from 2016 to 2020, Chairman at Lipideon Biotechnology AG, Chairman-Supervisory Board at SuppreMol GmbH from 2008 to 2015, Director at Caisse de dépôt et placement du Québec, Independent Director at IBEX Technologies, Inc., Director at Société Générale de Financement du Québec, Non-Executive Director at Kuur Therapeutics Ltd. from 2017 to 2020, Director at Humabs BioMed SA from 2013 to 2017, Independent Director at BioInvent International AB from 2020 to 2026, Co-Head-Bone Marrow Transplantation Program at the University of Freiburg, and Vice President-Marketing at Amgen (Europe) GmbH from 1989 to 2002.
Education includes a doctorate from the University of Freiburg, graduate studies at McGill University, and undergraduate studies at Sir George Williams University.